How to Choose an AI-Powered Systematic Literature Review Platform in 2027

Which SLR Platform to Choose: The Short Answer

Selecting the right AI-powered systematic literature review (SLR) platform in 2027 requires teams to prioritize validated screening accuracy, recall and precision, complete source-level traceability, configurable human oversight at every decision point, and native support for living reviews. Platforms that meet these standards help HEOR, medical affairs, and market access groups deliver audit-ready evidence faster while satisfying PRISMA and HTA expectations.

MadeAi achieves 90% accuracy in AI-assisted title and abstract screening. Additional validation measures include recall, precision, evidence relevance, and reasoning concordance, providing a broader assessment of screening performance and evidence retention.

Meanwhile, life sciences organizations face rising publication volumes and compressed regulatory timelines. A single, high-quality SLR once consumed six to sixteen months and significant specialist hours. Today, the same teams must support Joint Clinical Assessment (JCA) submissions, global value dossiers, clinical evaluation reports, and continuous surveillance. Traditional manual processes cannot scale. As a result, decision-makers evaluate AI-enabled platforms that accelerate high-volume tasks without eroding scientific rigor or auditability.

Why the Platform Decision Matters More in 2027

The decision matters because assessors now expect current, documented evidence on fixed clocks, and manual methods cannot deliver it at portfolio scale. An SLR is a protocol-driven synthesis of every study that meets predefined eligibility criteria, reported so that another team could reproduce it.

The Cost of a Manual Review

Borah et al. (2017) analyzed 195 completed reviews registered in PROSPERO and measured a mean of 67.3 weeks from registration to publication. Searches returned between 27 and 92,020 records at a mean yield of 2.94 percent, so reviewers spend most of their screening effort confirming that records are irrelevant. Michelson and Reuter (2019) separately estimated the cost of a single review at roughly $141,195. Those figures describe one review. A market access team preparing a global value dossier, three national submissions, and a network meta-analysis may run five or more.

The Regulatory Clock Is Now External

Under the EU HTA Regulation, JCAs began in January 2025 for oncology medicines and advanced therapies, extend to orphan medicines in 2028, and cover all new medicinal products from 2030 (European Commission, 2025).  Furthermore, the dossier guidance caps the search cut-off at three months before submission, half the six-month window that NICE methodologists work to. Each expansion enlarges the number of dossiers that need a current, fully documented evidence base inside a fixed window. Teams that rebuild each review from scratch cannot hold that pace, which is why pharma evidence generation solutions increasingly treat the SLR as a maintained asset rather than a one-time deliverable.

What Should an AI-Powered SLR Platform Do?

AI-Powered SLR Workflow: Five Stages

An AI-powered SLR platform should automate the high-volume steps of the review and leave every judgment with a named reviewer. The workflow has five stages, and a credible platform supports each one with logged, reviewable output:

1. Protocol and search design: PICO framing, query drafting, and search records that meet the PRISMA-S reporting checklist (Rethlefsen et al., 2021).
2. Screening: AI suggestions shared with two blinded human reviewers, or an AI second reviewer working in parallel with one human, at both title and abstract and full-text stages, with confidence scores and stated reasons.
3. Extraction: structured fields at summary and arm level, with source highlighting that shows where each value came from.
4. Appraisal and synthesis: risk-of-bias assessment, evidence tables, and single- and multi-article summaries.
5. Reporting and reuse: PRISMA flow diagrams, export packages, and scheduled living updates.

The architecture behind these stages matters as much as the feature list. A model that answers from its training weights behaves differently from one that retrieves records from a live index before generating text. Retrieval-grounded designs, described by Lewis et al. (2020) as retrieval-augmented generation, keep output tied to documents the reviewer can open. Ask every vendor which design their platform uses and how each assertion links back to a record identifier.

Which Seven Criteria Separate SLR Platforms in 2027?

Seven criteria separate platforms. Each comes with a question for the platform provider and a way to verify the answer on your own data.

Seven Checks for Choosing an AI Literature Review Platform

1. Validated Screening Recall

Ask for recall on published or client-matched datasets, not a blended accuracy figure. Recall is the share of truly relevant studies the model keeps, and it is the number assessors care about, because a missed trial is harder to defend than an extra hour of screening. The benchmark exists: the Cochrane RCT Classifier, calibrated for 99 percent recall, retrieved 43,783 of 44,007 randomized trials included in Cochrane reviews, and early Screen4Me pilots reported manual screening workload reductions of 40 to 70 percent (Thomas et al., 2021). By contrast, Clark et al. (2025) reviewed 19 comparative studies and found that generative AI used for searching missed a median of 91 percent of relevant studies. The lesson is to insist on performance evidence for the exact task the vendor automates, measured at the recall target you are willing to defend.

2. Extraction Accuracy by Data Type

Performance falls as fields get harder, so a single accuracy figure hides the risk. Sulaimanov et al. (2026) benchmarked four frontier models on structured extraction and measured 88.9 to 92.9 percent accuracy for simple categorical fields, 47.0 to 63.3 percent for medium-complexity text, and only 2.7 to 15.5 percent for variables that need clinical judgment or synthesis across sections. A strong platform routes numeric fields, effect estimates, confidence intervals, and event counts to mandatory human verification, uses model output as a first pass on descriptive fields, and logs the provenance of every value either way.

3. Decision-Level Audit Trails

Every AI suggestion needs a reason code, a model version, a threshold, and a named human sign-off. That expectation now carries institutional weight. NICE (2024) asks submitting organizations to justify AI use, prefer more explainable methods, and keep humans in decision-making. The joint position statement from Cochrane, the Campbell Collaboration, JBI, and CEE (2025), aligned to the RAISE recommendations, states that any AI use that makes or suggests judgments must be fully and transparently reported. A document-level audit trail no longer meets that bar.

4. Living Review Support

Scheduled re-runs, deduplication against the existing library, and version stamping for every strategy change turn a static review into a living SLR. Elliott et al. (2017) defined the living review as standard methods plus a predetermined update frequency, and the JCA three-month cut-off makes that cadence a compliance item rather than a methodological preference. Our analysis of living SLRs and JCA evidence mapping shows what the infrastructure looks like when the evidence base is indexed by PICO and re-cut when the scope changes.

5. Submission-Ready Outputs

PRISMA flow diagrams, evidence tables, screening logs with reasons, and exports that feed global value dossiers, JCA dossiers, and network meta-analyses save the weeks that reformatting usually costs market access solutions teams. Check that the platform exports in formats your health economists and medical writers already use, and that the same evidence base can serve several downstream deliverables without re-extraction.

6. Data Governance

Confirm whether your documents train vendor models, where data resides, who can access it, how long the vendor retains it, and which certifications cover the environment. Unpublished trial data and draft dossiers are among the most sensitive assets a company holds. Any AI platform for life sciences should answer these questions in writing before a pilot starts, and the answers should survive legal review.

7. Delivery Model Fit

Some teams want software only; others want expert-supported delivery or fully outsourced SLR services during peak periods. The platform should support all three without a change of tooling, so work can move between models as capacity shifts and the audit trail stays continuous across them.

Comparison Matrix: Three Ways to Run an SLR

What Do Teams Gain from the Right Platform?

The gains show up in time, consistency, and defensibility. Time to a refreshed evidence base drops from weeks to days once screening and first-pass extraction are automated. Consistency improves because one indexed library serves several PICOs and later national requirements. Defensibility strengthens because every automated decision and every human override is logged in a form an assessor can inspect. Resource allocation shifts from repetitive screening toward synthesis and strategic interpretation, which is where credentialed staff add the most value.

Where Does an SLR Platform Earn its Keep?

Three use cases recur across life sciences teams:

• A JCA submission in oncology: a living SLR covering the disease area runs continuously, so when the scope arrives with three PICO questions, the team filters the existing library and produces tailored evidence tables within days.
• A clinical evaluation report for a medical device: continuous post-market surveillance feeds the same workflow, and each update version-stamps the search, screening, and extraction so notified bodies can trace changes.
• A portfolio of assets in one therapeutic area: shared infrastructure reduces the marginal cost of each new indication, and congress abstracts published after the initial search integrate on the next scheduled run.

How to Run a Platform Pilot Before You Commit

Run the pilot on a review you have already completed, because that gives you a ground truth no vendor demo can. Follow these five steps:

1. Pick one completed SLR with a known included set and a documented search.
2. Re-run screening on the platform and calculate recall against your inclusions, then review every exclusion the model proposed.
3. Extract ten fields across categorical, numeric, and judgment types and measure agreement with your manual extraction.
4. Export the audit log and confirm a methodologist who did not run the pilot can reconstruct every decision.
5. Compare the result with the internal hours the manual review consumed, including rework.

Conversational research tools can shorten scoping before the pilot begins by turning a clinical question into an inspectable, exportable query; see how a conversational AI literature review changes evidence search.

Best Practices for Governed Adoption

Successful deployments share five habits. First, ground every review in a registered protocol that follows PRISMA and Cochrane standards, because transparency builds trust with assessors. Second, keep a human reviewer on every final inclusion, extraction, and synthesis decision, and document the model’s recall, precision, and known limitations so reviewers can judge reliability. Third, design the data model around PICO elements from the start so the library can be filtered when assessment questions change. Fourth, set governance for updates: define triggers for full versus incremental review and keep version control of the evidence map. Fifth, prepare for audit by retaining complete search logs, screening decisions, and prompt histories.

Risks and Limitations to Weigh

AI assistance introduces risks a buyer should name up front. Model performance varies by therapeutic area, study design, and document quality, and extraction from complex tables or poorly structured full texts remains error-prone. Fluent output invites over-trust: Walters and Wilder (2023) reported in Scientific Reports that 55 percent of GPT-3.5 and 18 percent of GPT-4 citations were fabricated, which is why retrieval grounding and citation verification stay mandatory. Coverage limits persist too, since a platform that searches only PubMed misses conference abstracts, regulatory documents, and registry entries that HTA bodies expect to see searched. HTA guidance on AI remains uneven across agencies, so conservative, well-documented methods stay the safest default. A platform reduces these risks only when the workflow builds in human oversight rather than relying on team discipline.

SLR Trends in 2028

Three shifts will reshape the market. Reporting standards for AI-assisted synthesis are consolidating around the RAISE recommendations, which makes disclosure routine and harder to skip. Portfolio load rises as JCA scope expands to orphan medicines in 2028 and all new medicines in 2030, which turns per-review effort into an operating model question. And the same evidence base that feeds a JCA will feed living guidelines, national appraisals, and dossier updates, so the value of maintaining it keeps rising. Expect AI in Life Science evidence work to converge on continuously maintained, PICO-indexed libraries with assertion-level traceability.

Conclusion

Knowing how to choose an SLR platform starts with methods, not software. Score recall, extraction by data type, audit trails, living support, outputs, governance, and delivery fit, then verify each score on your own completed review. MadeAi builds its literature review workflow around these controls, with source attribution at every step and support for software-only, expert-supported, and outsourced delivery. The practical next step is small: run one completed review through any shortlisted platform, compare the included set and audit log with your manual result, and let the evidence decide.

Author’s Note: This article was supported by AI-based research and writing, with Claude 5.1 assisting in the creation of text and images.